{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:52Z","timestamp":1791478312182,"version":"4.3.4"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"Abstract<\/jats:title>\n Dual antiplatelet therapy (DAPT) is essential after percutaneous coronary intervention (PCI). Current guidelines recommend 6 to 12 months of DAPT, but managing thrombotic and bleeding risks is challenging, especially in patients with both high bleeding risk (HBR) and high thrombotic risk (HTR).<\/jats:p>\n This study aimed to characterize a contemporary dual-risk PCI population (HBR and HTR) and used the Academic Research Consortium (ARC) trade-off model to determine the predominant risk (bleeding or thrombosis) to support personalized DAPT management.<\/jats:p>\n All patients who underwent PCI between November 2019 and December 2023 were screened. Dual-risk patients were identified using ARC-HBR criteria for bleeding and European Society of Cardiology (ESC) thrombotic criteria. The ARC trade-off model further stratified these patients into three groups: DRBR<TR, DRBR=TR, and DRBR>TR, based on whether the risk of death from bleeding was lower, similar, or higher than the risk of death from thrombosis. The primary outcome was net adverse clinical events (NACE), defined as a composite of all-cause death, myocardial infarction (MI), stent thrombosis (ST), or major bleeding. Secondary outcomes included individual components of NACE.<\/jats:p>\n Among 3,051 PCI patients, 12.4% were identified as dual-risk. The trade-off model stratified these patients into DRBR<TR (56.1%), DRBR=TR (29.6%), and DRBR>TR (14.3%) groups. At 18 months, the DRBR>TR group showed a significantly increased risk of NACE (HR 1.77, 95% CI, 1.04 to 3.03, p\u2009=\u20090.03) versus the DRBR=TR group, driven by higher rates of both major bleeding (HR 2.61, 95% CI, 1.08 to 6.67, p\u2009=\u20090.03) and MI\/ST (HR 3.36, 95% CI, 1.21 to 9.30, p\u2009=\u20090.02). These findings were confirmed in competing risk analysis using Fine\u2013Gray regression, both for bleeding (HR 3.0, 95% CI, 1.24 to 7.25; p\u2009=\u20090.015) and for thrombotic outcomes (HR 3.13, 95% CI, 1.14 to 8.64; p\u2009=\u20090.027).<\/jats:p>\n A contemporary trade-off model successfully stratified the dual-risk population, enabling personalized DAPT strategies for this complex population. Reducing bleeding risk in dual-risk patients may improve clinical outcomes.<\/jats:p>","DOI":"10.1055\/a-2862-6563","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:07:36Z","timestamp":1780096056000},"source":"Crossref","is-referenced-by-count":2,"title":["Bleeding and Thrombotic Trade-off in Dual-Risk Patients Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-9314","authenticated-orcid":false,"given":"Maria Sara","family":"Mauro","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Finocchiaro","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Catania Facolt\u00e0 di Medicina e Chirurgia, Italy","department":["Centro Alte Specialit\u00e0 e Trapianti & Azienda Ospedaliero Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Calderone","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele Catania, Italy","department":["Division of Cardiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-7402","authenticated-orcid":false,"given":"Claudio","family":"Laudani","sequence":"additional","affiliation":[{"name":"University of Catania, Italy","department":["Centro Alte Specialit\u00e0 e Trapianti"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[{"name":"CAST, P.O. \u201cRodolico\u201d, Azienda Ospedaliero-Universitaria \"Policlinico-Vittorio Emanuele\", University of Catania, Italy","department":["Division of Cardiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"University of Catania, Italy","department":["Cardiology Unit"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"17","key":"ref1","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"D J Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"J Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"38","key":"ref3","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"R A Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"D Capodanno","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2023.04.036","article-title":"Eligibility to intensified antithrombotic regimens for secondary prevention in patients who underwent percutaneous coronary intervention","volume":"199","author":"A Greco","year":"2023","journal-title":"Am J Cardiol"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4244\/EIJ-D-20-01197","article-title":"Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis","volume":"17","author":"R Piccolo","year":"2021","journal-title":"EuroIntervention"},{"issue":"13","key":"ref8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"G Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/CIRCULATIONAHA.124.069012","article-title":"Demystifying the contemporary role of 12-month dual antiplatelet therapy after acute coronary syndrome","volume":"150","author":"M Valgimigli","year":"2024","journal-title":"Circulation"},{"key":"ref10","first-page":"e013450","article-title":"Navigating the course of dual antiplatelet therapy after percutaneous coronary intervention: a review of guided approaches","volume":"e013450","author":"N Ammirabile","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"issue":"21","key":"ref11","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients","volume":"75","author":"D Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"e008307","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307","article-title":"Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention","volume":"12","author":"M Natsuaki","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Y Ueki","year":"2020","journal-title":"EuroIntervention"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"P Urban","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"J P Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamacardio.2020.6814","article-title":"Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC-high bleeding risk trade-off model","volume":"6","author":"P Urban","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"17","key":"ref17","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"G Giustino","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"ref18","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"R Mehran","year":"2011","journal-title":"Circulation"},{"issue":"18","key":"ref19","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"K Thygesen","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"ref20","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/eurheartj\/ehy223","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"39","author":"H M Garcia-Garcia","year":"2018","journal-title":"Eur Heart J"},{"issue":"446","key":"ref21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"J P Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"G S Collins","year":"2015","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"B Van Calster","year":"2019","journal-title":"BMC Med"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00392-018-1392-2","article-title":"Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry","volume":"108","author":"K Moalem","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2023.2291865","article-title":"Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management","volume":"22","author":"C Laudani","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamacardio.2021.1558","article-title":"Trade-off between bleeding and thrombotic risk in patients with Academic Research Consortium for high bleeding risk","volume":"6","author":"H Hara","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"D Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"14","key":"ref28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1161\/CIRCULATIONAHA.123.067583","article-title":"Coronary angiography, intravascular ultrasound, and optical coherence tomography for guiding of percutaneous coronary intervention: a systematic review and network meta-analysis","volume":"149","author":"D Giacoppo","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jcin.2024.04.020","article-title":"Rethinking aspirin: ditching the daily \u201cPill\u201dar of tradition","volume":"17","author":"S Finocchiaro","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.31083\/j.rcm2310348","article-title":"P2Y12 inhibitor monotherapy: considerations for acute and long-term secondary prevention post-PCI","volume":"23","author":"A Greco","year":"2022","journal-title":"Rev Cardiovasc Med"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"C Laudani","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvae002","article-title":"Pharmacological and clinical appraisal of factor XI inhibitor drugs","volume":"10","author":"G Occhipinti","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"A Greco","year":"2023","journal-title":"Circulation"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","article-title":"Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: the OPT-BIRISK randomized clinical trial","volume":"9","author":"Y Li","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1055\/a-2544-6263","article-title":"Antiplatelet therapy in percutaneous coronary intervention patients with concurrent high ischemic and bleeding risk","volume":"125","author":"M S Mauro","year":"2025","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"F Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","article-title":"Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"68","author":"J A Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"ref38","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.jcin.2024.08.027","article-title":"International consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update","volume":"17","author":"D J Angiolillo","year":"2024","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2862-6563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:05:56Z","timestamp":1780527956000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2862-6563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1055\/a-2862-6563","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}